Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.315 EUR -1.1% Market Closed
Market Cap: 36.3m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Cash from Financing Activities
€21.6m
CAGR 3-Years
-27%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash from Financing Activities
€72.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Cash from Financing Activities
-€7.6m
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Cash from Financing Activities
€53.8m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Financing Activities
-€23.5m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Cash from Financing Activities
€8m
CAGR 3-Years
-27%
CAGR 5-Years
104%
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
36.3m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.171 EUR
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Cash from Financing Activities?
Cash from Financing Activities
21.6m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Cash from Financing Activities amounts to 21.6m EUR.

What is Gensight Biologics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
23%

Over the last year, the Cash from Financing Activities growth was 121%. The average annual Cash from Financing Activities growth rates for Gensight Biologics SA have been -27% over the past three years , 23% over the past five years .

Back to Top